L3VLUP
ProSign in

IDXX · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IDXXLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IDXX
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterIDXXLLY
Q3 202018 holders, $2.9bn33 holders, $14.1bn
Q4 202015 holders, $3.5bn29 holders, $17.3bn
Q1 202122 holders, $3.5bn24 holders, $23.0bn
Q2 202118 holders, $4.5bn24 holders, $27.8bn
Q3 202120 holders, $4.6bn31 holders, $29.9bn
Q4 202117 holders, $4.9bn31 holders, $34.7bn
Q1 202218 holders, $4.7bn24 holders, $35.3bn
Q2 202220 holders, $3.5bn33 holders, $42.7bn
Q3 202217 holders, $2.7bn31 holders, $43.4bn
Q4 202213 holders, $3.5bn31 holders, $46.6bn
Q1 202318 holders, $4.2bn33 holders, $44.3bn
Q2 202316 holders, $3.7bn37 holders, $59.6bn
Q3 202315 holders, $3.2bn44 holders, $67.6bn
Q4 202316 holders, $4.1bn45 holders, $73.6bn
Q1 202417 holders, $3.7bn41 holders, $95.3bn
Q2 202413 holders, $3.7bn43 holders, $110bn
Q3 202417 holders, $3.8bn45 holders, $107bn
Q4 202422 holders, $2.6bn46 holders, $93.9bn
Q1 202517 holders, $2.4bn42 holders, $98.4bn
Q2 202511 holders, $2.5bn43 holders, $93.2bn
Q3 202510 holders, $2.8bn39 holders, $86.7bn
Q4 202514 holders, $5.1bn41 holders, $123bn
Q1 202616 holders, $4.7bn39 holders, $106bn
Q2 202622 holders, $4.9bn44 holders, $132bn
IDXX

Idexx Labs Inc

Holders
16
Reported value
$4.7bn
Buyers
23
Sellers
13

Breadth +10 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IDXX (1)

Freestone Grove Partners LP

Only LLY (24)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Renaissance Technologies LLC, Soros Fund Management LLC, Tudor Investment Corp, Two Sigma Investments LP, Voloridge Investment Management LLC, Walleye Capital LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →